Melanoma Medications
Here's a list of the approved drugs to treat melanoma. Click on any of the medications for more info on indications, dosing and side effects.
Quick Filter
*generic version available
E experimental
Chemotherapy Medications
Immunotherapy Medications
Targeted Therapy Medications
Chemotherapy Medications More >>
DRUG Chemotherapy |
---|
GENERIC NAME Multiple |
DRUG INDICATION
Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here. |
Immunotherapy Medications More >>
DRUG Keytruda |
---|
GENERIC NAME pembrolizumab |
DRUG INDICATION
Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, relapsed or refractory classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma and triple-negative breast cancer. It is also approved for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency mutations (MSI-H/dMMR) or high tumor mutation burden. |
DRUG Opdivo |
---|
GENERIC NAME nivolumab |
DRUG INDICATION
Opdivo is a checkpoint inhibitor approved for inoperable or metastatic melanoma, metastatic or recurrent non-small-cell lung cancer, advanced kidney cancer, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, advanced or metastatic bladder (urothelial) cancer, liver cancer, recurrent or metastatic esophageal cancer, malignant pleural mesothelioma and colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations. |
DRUG Tecentriq |
---|
GENERIC NAME atezolizumab |
DRUG INDICATION
Tecentriq is a checkpoint inhibitor approved for the treatment of advanced or metastatic bladder (urothelial) cancer, metastatic non-small-cell lung cancer, extensive-stage small-cell lung cancer, triple-negative breast cancer, metastatic liver cancer and inoperable or metastatic melanoma. |
DRUG Yervoy |
---|
GENERIC NAME ipilimumab |
DRUG INDICATION
Yervoy is a checkpoint inhibitor approved for advanced or metastatic melanoma, and in combination with Opdivo for kidney cancer (renal cell carcinoma), colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations (MSI-high/dMMR), advanced liver cancer and metastatic or recurrent non-small-cell lung cancer. |
Targeted Therapy Medications More >>
DRUG Braftovi |
---|
GENERIC NAME encorafenib |
DRUG INDICATION
Braftovi is a kinase inhibitor approved as a component of targeted therapy for metastatic melanoma and metastatic colorectal cancer. |
DRUG Cotellic |
---|
GENERIC NAME cobimetinib |
DRUG INDICATION
Cotellic is a kinase inhibitor approved to treat inoperable or metastatic melanoma with BRAF V600E or V600K mutations in combination with Zelboraf (vemurafenib). |
DRUG Gleevec |
---|
GENERIC NAME imatinib |
DRUG INDICATION
Gleevec, a kinase inhibitor, was one of the first targeted therapies for cancer treatment. It is approved for many indications including Philadelphia chromosome positive (Ph+) chronic myeloid leukemia and acute lymphoblastic leukemia, chronic eosinophilic leukemia, mastocytosis and gastrointestinal stromal tumor. |
DRUG Mekinist |
---|
GENERIC NAME trametinib |
DRUG INDICATION
Mekinist is a kinase inhibitor approved to treat certain cancers with BRAF V600 mutations. It can be used alone to treat people with inoperable or metastatic melanoma. It is approved in combination with the companion drug Tafinlar for treatment of inoperable or metastatic melanoma and for prevention of melanoma recurrence after surgery. The combination is also approved for metastatic non-small-cell lung cancer (NSCLC) and advanced thyroid cancer. |
DRUG Mektovi |
---|
GENERIC NAME binimetinib |
DRUG INDICATION
Mektovi is a kinase inhibitor approved to treat inoperable or metastatic melanoma with BRAF V600E or V600K mutations in combination with Braftovi (encorafenib). |
DRUG Tafinlar |
---|
GENERIC NAME dabrafenib |
DRUG INDICATION
Tafinlar is a kinase inhibitor approved to treat certain cancers with BRAF V600 mutations. It can be used alone to treat people with inoperable or metastatic melanoma. It is approved in combination with the companion drug Mekinist for treatment of inoperable or metastatic melanoma and for prevention of melanoma recurrence after surgery. The combination is also approved for metastatic non-small-cell lung cancer (NSCLC) and advanced thyroid cancer. |
DRUG Tasigna |
---|
GENERIC NAME nilotinib |
DRUG INDICATION
Tasigna is a kinase inhibitor approved for newly diagnosed or previously Philadelphia chromosome positive (Ph+) chronic myeloid leukemia. |
DRUG Zelboraf |
---|
GENERIC NAME vemurafenib |
DRUG INDICATION
Zelboraf is a kinase inhibitor approved for inoperable or metastatic melanoma with BRAF V600E mutations and Erdheim-Chester Disease with BRAF V600 mutations. |